You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

144 Results
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    fulvestrant
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria
Feb 2021
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
Exceptional Access Program
    trametinib - In combination with dabrafenib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
Jun 2021
Drug
Other Name(s): Retevmo™
Updated
Apr 2025
Drug
Other Name(s): Brukinsa®
Apr 2024
Drug
Other Name(s): Lynparza®
Jan 2025
Drug
Other Name(s): Calquence®
Jul 2024
Drug
Other Name(s): Jakavi®
Mar 2025
Drug
Other Name(s): Xpovio®
Mar 2024
Drug
Other Name(s): Onureg®
Aug 2023
Drug
Other Name(s): Inrebic®
Jan 2025
Drug
Other Name(s): Tagrisso®
Jan 2024
Drug
Other Name(s): Verzenio®
Feb 2025

Pages